BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Evaxion Biotech Announces Proof-of-Concept for AI-Driven Cancer Vaccines Targeting Endogenous Retrovirus Tumor Antigens

by BiopharmaTrend    •   Dec. 13, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Novel Therapeutics   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company, has announced preclinical Proof-of-Concept (PoC) results for a precision cancer vaccine concept. The approach uses the company’s AI-Immunology platform to target shared non-conventional endogenous retrovirus (ERV) tumor antigens, potentially expanding options for cancer immunotherapy.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

This development follows Evaxion’s earlier achievements in applying artificial intelligence to identify neoantigens for personalized cancer vaccines. The platform integrates technologies such as PIONEER, EDEN, RAVEN, and ObsERV to support vaccine development in oncology and infectious diseases.

See also: Evaxion's AI-Immunology Platform Gains Validation in Clinical Trials

Evaxion’s new method identifies ERVs expressed in cancer cells as potential tumor antigens. ERVs, embedded viral elements in the human genome, can reactivate in cancer and serve as novel therapeutic targets. The ObsERV model plays a central role in identifying these ERV-derived targets.

By selecting ERV fragments, or "hotspots," compatible with diverse immune profiles, the concept aims to enable the development of vaccines that could be applied to multiple cancer types. Unlike conventional cancer vaccines that rely on identifying neoantigens from tumors with high mutational burden (TMB), this approach may be suitable for cancers with lower TMB, broadening the potential patient population.

Palexpo exhibition centre in Geneva, Switzerland

Preclinical Results

The PoC data, presented at the ESMO Immuno-Oncology Congress in Geneva, Switzerland, highlights the following findings:

  • Human Immune Cell Studies: ERV targets stimulated T-cell responses across samples from multiple donors.
  • Mouse Models: ERV precision vaccines induced antigen-specific T-cells and reduced tumor growth.

Evaxion intends to identify a lead vaccine candidate in the second half of 2025.

Evaxion Biotech

Topics: Novel Therapeutics   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.